Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis
Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis
复制标题
DOI：
10.1111/j.1365-2559.2007.02619.x
复制
发表时间：
2007-03-01
期刊：
影响因子：
6.4
通讯作者：
Gosheger, G.
中科院分区：
文献类型：
--
作者：
Gebert, C.;Hardes, J.;Gosheger, G.
目的：探讨β-连环蛋白在侵袭性纤维瘤病中的预后意义，为侵袭性纤维瘤病的新的靶向治疗寻找潜在的分子标志物。方法与结果：构建了37例深部侵袭性纤维瘤病组织芯片，应用免疫组织化学方法检测了β-连环素、p53、SMA、结蛋白、Ki67、c-erbB2、表皮生长因子受体(EGFR)、c-kit、CD34和S100的表达。对23例患者进行了完整的临床随访。核β-连环蛋白的表达与肿瘤局部复发率的增加有关(60.0%的1年和0%的5年无事件生存率；P<；0.05)。此外，P53的表达与肿瘤复发的风险增加相关(50%的1年无事件生存率和0%的5年无事件生存率，P<；0.05)。P53和β-连环蛋白的共同表达显著相关(P<；0.05)。MIB1和P53或β-连环蛋白的表达之间没有统计学意义的相关性。结论：深部侵袭性纤维瘤病中β-连环蛋白和P53的过度表达与无事件生存率降低有关。需要进一步的研究来确定这些发现是否可以改善这种罕见肿瘤的治疗。
Aims: To determine the prognostic significance of beta-catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies.Methods and resulits: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for beta-catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c-erbB2, epidermal growth factor receptor (EGFR), c-kit, CD34 and S100. Complete clinical follow-up was available for 23 patients. Nuclear beta-catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1-year and 0% 5-year event-free survival; P < 0.05). Furthermore, p53 expression was associated with an increased risk of tumour recurrence (50% 1-year event-free survival rate and 0% 5-years event-free survival rate, P < 0.05). The coexpression of p53 and beta-catenin was significantly correlated (P < 0.05). No statistically significant association was seen between MIB1 and p53 or beta-catenin expression, respectively. No expression of EGFR, c-erbB2 or c-kit was seen.Conclusions: The overexpression of beta-catenin and p53 is associated with a decreased event-free survival in deep aggressive fibromatosis. Further studies are required to establish whether these findings can lead to an improvement in the treatment of this rare neoplasm.